Literature DB >> 32041417

Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis.

Qianyi Gong1, Changfeng Song1, Xiaotong Wang1, Renjie Wang2,3, Guoxiang Cai2,3, Xin Liang1, Jianwen Liu1.   

Abstract

Entities:  

Keywords:  Recombinant mutant human TNF-α; colorectal cancer; hyperthermia; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis; raltitrexed

Mesh：

Substances：

Year:  2020        PMID： 32041417      PMCID： PMC7158601          DOI： 10.1177/1535370220905047

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  47 in total

1.  Phase II multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-α in combination with chemotherapies in cancer patients.

Authors:  Meng Li; Tianjiao Xu; Zhao Zhang; Xiaochang Xue; Cun Zhang; Xin Qin; Weina Li; Qiang Hao; Wei Zhang; Yingqi Zhang
Journal:  Cancer Sci       Date:  2012-01-09       Impact factor: 6.716

2.  Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin.

Authors:  Wansheng Ji; Mingliang Yuan; Li Zhang; Hongmei Zhang; Jianxin Jiao; Zhixing Gao
Journal:  Mol Med Rep       Date:  2017-04-04       Impact factor: 2.952

Review 3.  Clinical applications of TNF-alpha in cancer.

Authors:  F J Lejeune; C Rüegg; D Liénard
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

4.  Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.

Authors:  D Ransom; K Wilson; M Fournier; R J Simes; V Gebski; D Yip; N Tebbutt; C S Karapetis; D Ferry; S Gordon; T J Price
Journal:  Ann Oncol       Date:  2013-12-02       Impact factor: 32.976

Review 5.  Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events.

Authors:  Joseph L Roti Roti
Journal:  Int J Hyperthermia       Date:  2008-02       Impact factor: 3.914

Review 6.  Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective.

Authors:  Madalyn G Neuwirth; H Richard Alexander; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

7.  The loss of MiR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling.

Authors:  Rurong Maoa; Fangyuan Zou; Liyan Yang; Shengchao Lin; Yueqi Li; Mingxing Ma; Peihao Yin; Xin Liang; Jianwen Liu
Journal:  Int J Biochem Cell Biol       Date:  2015-12       Impact factor: 5.085

8.  Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.

Authors:  Joerg O W Pelz; Terence C Chua; Jesus Esquivel; Alexander Stojadinovic; Joerg Doerfer; David L Morris; Uwe Maeder; Christoph-Thomas Germer; Alexander G Kerscher
Journal:  BMC Cancer       Date:  2010-12-22       Impact factor: 4.430

9.  S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.

Authors:  Ye Chen; Jing Wu; Ke Cheng; Zhi-Ping Li; De-Yun Luo; Meng Qiu; Hong-Feng Gou; Cheng Yi; Qiu Li; Xin Wang; Yu Yang; Dan Cao; Ya-Li Shen; Feng Bi; Ji-Yan Liu
Journal:  Oncologist       Date:  2019-01-16

10.  Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.

Authors:  Hongwei Zhao; Yubao Zhang; Jianmin Sun; Chao Zhan; Liang Zhao
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574
View more
  1 in total

Review 1.  Clinical translation of immunomodulatory therapeutics.

Authors:  Amanda Nash; Samira Aghlara-Fotovat; Andrea Hernandez; Christopher Scull; Omid Veiseh
Journal:  Adv Drug Deliv Rev       Date:  2021-07-27       Impact factor: 17.873
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.